Clinical study of remazolam toluenesulfonate and dexmedetomidine in ICU patients with mechanical ventilation

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2200056041

Enrollment

Unknown

Registered

2022-01-31

Start date

2022-09-01

Completion date

Unknown

Last updated

2024-08-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Respiratory failure due to sepsis

Interventions

Remazolam toluenesulfonic sedation group:Remazolam toluene sulfonate

Dexmedetomidine sedation group: Dexmedetomidine

Eligibility

Sex/Gender

All

Age

18 Years to 60 Years

Inclusion criteria

Inclusion criteria: 1. Aged > 18 and = 3 and RASS > 2; 3. GCS score > 8; 4. Mechanical ventilation time in ICU >24h; 5. ICU inpatients > 48 hours; 6. Signed informed consent.

Exclusion criteria

Exclusion criteria: 1. Pregnancy or breastfeeding; 2. Patients with a history of alcohol or drug abuse; 3. Patients without sedation and analgesia; 4. Bradycardia (DEGREE II/III Atrioventricular block), right bundle branch block; 5. Receiving 2 or more sedative or analgesic drugs within 24 hours; 6. Patients allergic to remazolam, dexmedetomidine, or remifentanil.

Design outcomes

Primary

Measure	Time frame
RASS score;vital signs;length of ICU stay;CAM score - the ICU;ACTH concentration;C-P concentration;TICS - T score;	—

Countries

China

Contacts

Public ContactChunbo Yang

The First Affiliated Hospital of Xinjiang Medical University

271251516@qq.com+86 15199142601

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026